title: Does CDKN2A loss predict palbociclib benefit?
abstract: Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer. Patients with loss of CDKN2A (p16), an inherent negative regulator of cyclin-dependent kinases 4 and 6, were not separately studied because of the significant response of the patients selected based only on receptor status. Here, we report a patient with metastatic estrogen receptor- positive, her2-negative breast cancer with CDKN2A loss who experienced a clinical response to palbociclib.
authors.affiliation: National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.;
authors.forename: J
authors.initials: J
authors.lastname: Gao
authors.forename: R P
authors.initials: RP
authors.lastname: Adams
authors.forename: S M
authors.initials: SM
authors.lastname: Swain
keywords: Medical oncology; breast cancer